Boston, Massachusetts ( — The tiny particles of asbestos that cause lung cancer, mesothelioma, and high risk of gastrointestinal, colorectal, throat, kidney, esophagus, and gallbladder cancer have been found in many office buildings, universities and classrooms across America and Canada.

When mesothelioma develops, malignant cells also begin to develop in the mesothelium, a protective lining that covers most of the body’s internal organs. The severity of mesothelioma led an Isreali medical research firm to develop new technology and methods to fight this cancer. The firm, Rosetta Genomics, recently advanced its newest cancer diagnostic test called microRNA testing which may offer early diagnosis of mesothelioma cancer.

One of the greatest difficulties in treating malignant mesothelioma is that the disease is rarely diagnosed early. This new test was soon validated by Columbia University Medical Center and has therefore been approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program. The main aspect of the test draws a simple blood sample and then explores the cells of the patient’s tumor and has a 96% sensitivity and a 90% specificity.  According to an article in Trans World News, “this is the first test utilizing microRNAs’ unique sensitivity and specificity as biomarkers that may offer a standardized and objective method for lung cancer classification.”

Rosetta Genomics plans to continue their research within the United States in their newly purchased Parkway Clinical Laboratories, in Bensalem, Pennsylvania. If successful, the company will submit the new diagnostic test for approval during 2008.

For more news on Mesothelioma, please subscribe to our mesothelioma RSS feeds

Boston Mesothelioma Lawyer / News Reporter